Zimmer Biomet Holdings, Inc. (ZBH) Analysts See $1.87 EPS; Atossa Genetics (ATOS) Shorts Up By 17.8%

April 17, 2018 - By Marie Mckinney

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Logo

Atossa Genetics Inc (NASDAQ:ATOS) had an increase of 17.8% in short interest. ATOS’s SI was 3.55M shares in April as released by FINRA. Its up 17.8% from 3.01M shares previously. With 1.91 million avg volume, 2 days are for Atossa Genetics Inc (NASDAQ:ATOS)’s short sellers to cover ATOS’s short positions. The stock decreased 12.82% or $0.053 during the last trading session, reaching $0.361. About 2.29M shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 57.26% since April 17, 2017 and is downtrending. It has underperformed by 68.81% the S&P500.

Analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to report $1.87 EPS on April, 26 before the open.They anticipate $0.26 EPS change or 12.21% from last quarter’s $2.13 EPS. ZBH’s profit would be $379.95M giving it 14.34 P/E if the $1.87 EPS is correct. After having $2.10 EPS previously, Zimmer Biomet Holdings, Inc.’s analysts see -10.95% EPS growth. The stock increased 1.58% or $1.67 during the last trading session, reaching $107.24. About 1.33M shares traded or 5.26% up from the average. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has declined 9.82% since April 17, 2017 and is downtrending. It has underperformed by 21.37% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $11.49 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, makes, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has market cap of $21.79 billion. It operates through four divisions: Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic , and Dental. It has a 12.05 P/E ratio. The firm provides orthopedic reconstructive products, such as knee and hip reconstructive products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Among 33 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 23 have Buy rating, 1 Sell and 9 Hold. Therefore 70% are positive. Zimmer Biomet Holdings had 96 analyst reports since August 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, September 4 by Canaccord Genuity. As per Friday, July 28, the company rating was maintained by Leerink Swann. Needham maintained it with “Buy” rating and $150 target in Friday, July 29 report. On Wednesday, November 1 the stock rating was maintained by SunTrust with “Buy”. Jefferies maintained Zimmer Biomet Holdings, Inc. (NYSE:ZBH) on Thursday, December 21 with “Buy” rating. The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) earned “Buy” rating by Piper Jaffray on Thursday, September 28. Guggenheim initiated Zimmer Biomet Holdings, Inc. (NYSE:ZBH) on Thursday, June 9 with “Neutral” rating. The rating was maintained by Piper Jaffray with “Buy” on Thursday, July 27. The stock has “Buy” rating by RBC Capital Markets on Monday, November 6. The firm has “Sell” rating given on Thursday, December 15 by UBS.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: